Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2009-3-3
pubmed:abstractText
Overexpression of the human epidermal growth factor receptor 2 (HER2) in breast tumors is associated with bad prognosis. Therefore, it is highly relevant to further improve understanding of the regulatory mechanisms of HER2 expression. In addition to gene amplification, transcriptional regulation plays a crucial role in HER2 overexpression. In this study, we analyzed 3 polymorphisms E2F2_-5368_A>G, CCND1_870_A>G and CCND3_-677_C>T located in genes involved in cell cycle regulation in the GENICA population-based and age-matched breast cancer case-control study from Germany. We genotyped 1,021 cases and 1,015 controls by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Statistical analyses were performed by conditional logistic regression. We observed no differences in genotype frequencies between breast cancer cases and controls. Subgroup analysis showed associations between carriers of the E2F2_-5368_G allele (OR: 0.60, 95% CI: 0.42-0.85), carriers of the CCND1_870_G allele (OR: 0.66, 95% CI: 0.45-0.96) and carriers of the CCND3_-677_T allele (OR: 1.72, 95% CI: 1.20-2.49) and HER2 expression in breast tumors. This finding points to an association of an increased expression of these cell cycle regulators with lower expression of HER2. An explanation for this observation might be that low expression of E2F2, CCND1 and CCND3 decrease levels of factors down-regulating HER2. We conclude that the analyzed polymorphisms located in E2F2, CCND1 and CCND3 are potential markers for HER2 status of breast tumors.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1097-0215
pubmed:author
pubmed:copyrightInfo
(c) 2008 Wiley-Liss, Inc.
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
124
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2077-81
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:19142864-Binding Sites, pubmed-meshheading:19142864-Breast Neoplasms, pubmed-meshheading:19142864-Case-Control Studies, pubmed-meshheading:19142864-Cyclin D1, pubmed-meshheading:19142864-Cyclin D3, pubmed-meshheading:19142864-Cyclins, pubmed-meshheading:19142864-DNA Mutational Analysis, pubmed-meshheading:19142864-E2F2 Transcription Factor, pubmed-meshheading:19142864-Female, pubmed-meshheading:19142864-Genotype, pubmed-meshheading:19142864-Germany, pubmed-meshheading:19142864-Humans, pubmed-meshheading:19142864-Immunoenzyme Techniques, pubmed-meshheading:19142864-Middle Aged, pubmed-meshheading:19142864-Neoplasm Staging, pubmed-meshheading:19142864-Polymorphism, Genetic, pubmed-meshheading:19142864-Prognosis, pubmed-meshheading:19142864-Receptor, erbB-2, pubmed-meshheading:19142864-Spectrometry, Mass, Matrix-Assisted Laser..., pubmed-meshheading:19142864-Transcription Factors, pubmed-meshheading:19142864-Tumor Markers, Biological
pubmed:year
2009
pubmed:articleTitle
Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors.
pubmed:affiliation
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't